/
Oncology
B-Cell Lymphoid Malignancies
6
Pipeline Programs↗
1
Active Trials↗
8
Companies Involved↗
B-cell Lymphoid Malignancies is an early-stage landscape with 6 programs across 8 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical
No programs
Phase 16
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
5 of 6 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 100% of 6 pipeline programs.
Analysis
Trial Status
8
clinical trials
Completed4 · 50%
Withdrawn2 · 25%
Terminated1 · 13%
Active, not recruiting1 · 13%
Clinical Trials
Trial Activity
8 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)